Literature DB >> 15197213

Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy.

Ryuichiro Kumasaka1, Norio Nakamura, Kenichi Shirato, Hiroshi Osawa, Shingo Takanashi, Yukihiro Hasegawa, Hideaki Yamabe, Masayuki Nakamura, Michiko Tamura, Ken Okumura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15197213     DOI： 10.1200/JCO.2004.09.064

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Acute renal failure associated with gefitinib therapy.

Authors:  Hsiang-Lin Wan; Nai-Shun Yao
Journal:  Lung       Date:  2006 Jul-Aug       Impact factor: 2.584

Review 2.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

3.  A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma.

Authors:  Tomohiro Kaneko; Akira Shimizu; Michiko Aoki; Shuichi Tsuruoka
Journal:  CEN Case Rep       Date:  2014-07-18

Review 4.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

Review 5.  Renal toxicity of targeted therapies.

Authors:  Ronan J Kelly; Bertrand Billemont; Olivier Rixe
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493

Review 6.  Renal toxicity of anticancer agents targeting HER2 and EGFR.

Authors:  Laura Cosmai; Maurizio Gallieni; Camillo Porta
Journal:  J Nephrol       Date:  2015-09-04       Impact factor: 3.902

7.  Minimal change disease onset observed after bevacizumab administration.

Authors:  Ramy M Hanna; Eduardo Lopez; James Wilson; Shrinath Barathan; Arthur H Cohen
Journal:  Clin Kidney J       Date:  2015-12-28

8.  Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy.

Authors:  Noriaki Kurita; Naobumi Mise; Akiko Fujii; Shingo Ikeda; Tokuichiro Sugimoto
Journal:  NDT Plus       Date:  2009-12

Review 9.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Authors:  Kenar D Jhaveri; Rimda Wanchoo; Vipulbhai Sakhiya; Daniel W Ross; Steven Fishbane
Journal:  Kidney Int Rep       Date:  2016-09-21

10.  Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.

Authors:  Kohsuke Masutani; Kiichiro Fujisaki; Hiroto Maeda; Jiro Toyonaga; Ichiro Inoshima; Koichi Takayama; Ritsuko Katafuchi; Hideki Hirakata; Kazuhiko Tsuruya; Mitsuo Iida
Journal:  Clin Exp Nephrol       Date:  2008-06-25       Impact factor: 2.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.